John M Matsoukas

List of Publications by Year
in descending order

58	1,270	394421 19	377865 34
papers	citations	h-index	g-index

58	58	58	1256
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Human Myelin Proteome and Sub-Metalloproteome Interaction Map: Relevance to Myelin-Related Neurological Diseases. Brain Sciences, 2022, 12, 434.	2.3	2
2	Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2. Computational and Structural Biotechnology Journal, 2022, 20, 2091-2111.	4.1	18
3	Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. Viruses, 2022, 14, 1029.	3.3	17
4	New Advances in Short Peptides: Looking Forward. Molecules, 2022, 27, 3635.	3.8	9
5	Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockersâ€"Relevance to COVID-19. Biomolecules, 2021, 11, 979.	4.0	15
6	Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan. Brain Sciences, 2021, 11, 1583.	2.3	5
7	Myelin Peptideâ€"Mannan Conjugate Multiple Sclerosis Vaccines: Conjugation Efficacy and Stability of Vaccine Ingredient. Vaccines, 2021, 9, 1456.	4.4	6
8	The Use of Electrochemical Voltammetric Techniques and High-Pressure Liquid Chromatography to Evaluate Conjugation Efficiency of Multiple Sclerosis Peptide-Carrier Conjugates. Brain Sciences, 2020, 10, 577.	2.3	6
9	Mannan-MOG35-55 Reverses Experimental Autoimmune Encephalomyelitis, Inducing a Peripheral Type 2 Myeloid Response, Reducing CNS Inflammation, and Preserving Axons in Spinal Cord Lesions. Frontiers in Immunology, 2020, 11, 575451.	4.8	15
10	Advances in Multiple Sclerosis Researchâ€"Series I. Brain Sciences, 2020, 10, 795.	2.3	5
11	The Long Road of Immunotherapeutics against Multiple Sclerosis. Brain Sciences, 2020, 10, 288.	2.3	7
12	Cyclization of PLP139-151 peptide reduces its encephalitogenic potential in experimental autoimmune encephalomyelitis. Bioorganic and Medicinal Chemistry, 2018, 26, 2221-2228.	3.0	7
13	Design of Linear and Cyclic Mutant Analogues of Dirucotide Peptide (MBP82â€"98) against Multiple Sclerosis: Conformational and Binding Studies to MHC Class II. Brain Sciences, 2018, 8, 213.	2.3	4
14	Transdermal Delivery of AT1 Receptor Antagonists Reduce Blood Pressure and Reveal a Vasodilatory Effect on Kidney Blood Vessels. Current Molecular Pharmacology, 2018, 11, 226-236.	1.5	3
15	Cyclic MOG 35 â€" 55 ameliorates clinical and neuropathological features of experimental autoimmune encephalomyelitis. Bioorganic and Medicinal Chemistry, 2017, 25, 4163-4174.	3.0	11
16	Cyclic citrullinated MBP87â€"99 peptide stimulates T cell responses: Implications in triggering disease. Bioorganic and Medicinal Chemistry, 2017, 25, 528-538.	3.0	16
17	Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sciences, 2017, 7, 78.	2.3	197
18	Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens. International Journal of Molecular Sciences, 2016, 17, 1398.	4.1	26

#	Article	IF	Citations
19	Immunoexpression patterns for Hypoxia-inducible Factor-1Î± and von Hippel-Lindau protein, in relation to Hsp90, of human brain tumors. Histology and Histopathology, 2016, 31, 535-46.	0.7	0
20	Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis. Frontiers in Immunology, 2015, 6, 136.	4.8	13
21	Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of multiple sclerosis. European Journal of Medicinal Chemistry, 2015, 101, 13-23.	5.5	17
22	Mannan-conjugated myelin peptides prime non-pathogenic Th1 and Th17 cells and ameliorate experimental autoimmune encephalomyelitis. Experimental Neurology, 2015, 267, 254-267.	4.1	36
23	Rational Design and Synthesis of Altered Peptide Ligands based on Human Myelin Oligodendrocyte Glycoprotein 35â€“55 Epitope: Inhibition of Chronic Experimental Autoimmune Encephalomyelitis in Mice. Molecules, 2014, 19, 17968-17984.	3.8	16
24	Rational design, efficient syntheses and biological evaluation of N , N â€²-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. European Journal of Medicinal Chemistry, 2013, 62, 352-370.	5.5	28
25	Microwave-assisted solid-phase peptide synthesis of the 60â€“110 domain of human pleiotrophin on 2-chlorotrityl resin. Amino Acids, 2011, 40, 1431-1440.	2.7	29
26	Design and Synthesis of a Cyclic Double Mutant Peptide (cyclo(87â^'99)[A⁹¹,A⁹⁶]MBP_{87â^'99}) Induces Altered Responses in Mice after Conjugation to Mannan: Implications in the Immunotherapy of Multiple Sclerosis. Journal of Medicinal Chemistry, 2009, 52, 214-218.	6.4	40
27	Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochimica Et Biophysica Sinica, 2008, 40, 636-642.	2.0	30
28	A double mutation of MBP83â€“99 peptide induces IL-4 responses and antagonizes IFN-Î³ responses. Journal of Neuroimmunology, 2008, 200, 77-89.	2.3	34
29	Design of Novel Cyclic Altered Peptide Ligands of Myelin Basic Protein MBP_{83â^'99}That Modulate Immune Responses in SJL/J Mice. Journal of Medicinal Chemistry, 2008, 51, 3971-3978.	6.4	50
30	Mannosylation of mutated MBP83â€“99 peptides diverts immune responses from Th1 to Th2. Molecular Immunology, 2008, 45, 3661-3670.	2.2	32
31	Citrullination of Linear and Cyclic Altered Peptide Ligands from Myelin Basic Protein (MBP_{87â^'99}) Epitope Elicits a Th1 Polarized Response by T Cells Isolated from Multiple Sclerosis Patients: Implications in Triggering Disease. Journal of Medicinal Chemistry, 2008, 51, 7834-7842.	6.4	47
32	Round and Round we Go: Cyclic Peptides in Disease. Current Medicinal Chemistry, 2006, 13, 2221-2232.	2.4	154
33	Structure and Function of the Myelin Proteins: Current Status and Perspectives in Relation to Multiple Sclerosis. Current Medicinal Chemistry, 2005, 12, 1569-1587.	2.4	37
34	Design And Synthesis of a Novel Potent Myelin Basic Protein Epitope 87â^'99 Cyclic Analogue:Â Enhanced Stability and Biological Properties of Mimics Render Them a Potentially New Class of Immunomodulatorsâ€. Journal of Medicinal Chemistry, 2005, 48, 1470-1480.	6.4	62
35	Modulation of Angiogenesis and Progelatinase a by Thrombin Receptor Mimetics and Antagonists. Endothelium: Journal of Endothelial Cell Research, 2001, 8, 195-206.	1.7	28
36	Modulation of Angiogenesis and Progelatinase a by Thrombin Receptor Mimetics and Antagonists. Endothelium: Journal of Endothelial Cell Research, 2001, 8, 195-206.	1.7	7

#	Article	IF	Citations
37	Design and Synthesis of a Potent Cyclic Analogue of the Myelin Basic Protein Epitope MBP72-85:â€‰ Importance of the Ala81 Carboxyl Group and of a Cyclic Conformation for Induction of Experimental Allergic Encephalomyelitis. Journal of Medicinal Chemistry, 1999, 42, 1170-1177.	6.4	48
38	Title is missing!. International Journal of Peptide Research and Therapeutics, 1998, 5, 305-315.	0.1	1
39	A comparative SAR study of thrombin receptor derived non peptide mimetics: Importance of phenyl/guanidino proximity for activity. Amino Acids, 1998, 15, 211-220.	2.7	5
40	Design and synthesis of potent tyr(OMe)5-gonadotropin-releasing hormone (GnRH) analogues with modifications at positions 6, 9 and 10. International Journal of Peptide Research and Therapeutics, 1998, 5, 305-315.	0.1	2
41	Design and synthesis of potent cyclic analogues and mimetics of myelin basic protein epitope MBP87-99 for suppression of experimental allergic encephalomyelitis (EAE). Expert Opinion on Therapeutic Targets, 1998, 2, 31-32.	1.0	0
42	Advances in antihypertensive therapy: Non-peptide angiotensin II receptor antagonists as potent therapeutic agents. International Journal of Peptide Research and Therapeutics, 1996, 3, 169-174.	0.1	1
43	Interactions of angiotensin II with membranes using a combination of differential scanning calorimetry and 31P NMR spectroscopy. International Journal of Peptide Research and Therapeutics, 1996, 3, 175-180.	0.1	7
44	Influence of sarmesin on the cardiac and vascular actions of angiotensin II. International Journal of Peptide Research and Therapeutics, 1996, 3, 181-184.	0.1	0
45	Influence of sarmesin on some dopamine-related types of behaviour. International Journal of Peptide Research and Therapeutics, 1996, 3, 185-190.	0.1	4
46	Biological activity of the novel cyclic angiotensin II analogue [Sar1,Lys3,Glu5]ANG II. International Journal of Peptide Research and Therapeutics, 1996, 3, 191-194.	0.1	7
47	Superimposition of potent non-peptide AT1 receptor antagonists with angiotensin II. International Journal of Peptide Research and Therapeutics, 1996, 3, 209-216.	0.1	8
48	Inhibition of TRAP-induced angiogenesis by the tripeptide Phe-Pro-Arg, a thrombin-receptor-derived peptide analogue. International Journal of Peptide Research and Therapeutics, 1996, 3, 227-232.	0.1	1
49	Synthesis and activities of cyclic thrombin-receptor-derived peptide analogues of the Ser42-Phe-Leu-Leu-Arg46 motif sequence containing d-Phe and/or d-Arg. International Journal of Peptide Research and Therapeutics, 1996, 3, 233-240.	0.1	4
50	Design and synthesis of a gonadotropin-releasing hormone (GnRH) analogue, [Tyr(OMe)5,d-Glu6,Aze9]GnRH: Receptor binding, gonadotropin release and ovulation studies. International Journal of Peptide Research and Therapeutics, 1996, 3, 257-262.	0.1	7
51	Design and Pharmacology of Peptide Mimetics. Advances in Pharmacology, 1995, 33, 91-141.	2.0	29
52	Receptor interactions of the position 4 side chains of angiotensin II analogues: Importance of aromatic ring quadrupole. Journal of Molecular Recognition, 1994, 7, 251-256.	2.1	7
53	Synthesis and biological activities of angiotensin II, sarilesin, and sarmesin analogs containing Aze or Pip at position 7. Journal of Medicinal Chemistry, 1993, 36, 904-911.	6.4	33
54	Synthesis and biological activities of angiotensin II and Sarmesin analogues containing cyclohexylalanine. International Journal of Peptide and Protein Research, 1991, 37, 21-26.	0.1	3

#	Article	IF	Citations
55	One pot synthesis and conformation of N-t-butyloxycarbonyl, O-Phenacyl derivatives of proline and other secondary amino acids. Tetrahedron, 1990, 46, 565-576.	1.9	35
56	Nmr and Mass Spectroscopic Studies of the Competitive-Angiotensin II Antagonist â€œSarmesinâ€• Spectroscopy Letters, 1988, 21, 477-491.	1.0	3
57	Angiotensin as a model for hormone â€“ receptor interactions. Bioscience Reports, 1985, 5, 407-416.	2.4	34
58	13C NMR of Some Malic Acid Derivatives. Spectroscopy Letters, 1983, 16, 933-943.	1.0	2